Recherches/Données

Black, D.M., Bentley, D., Chapel, S. et al. Clin Pharmacokinet (2018). https://doi.org/10.1007/s40262-018-0656-3

Rautureau Y., Deschambault V., Higgins M. E., et. al. Adenylate Cyclase Type 9 (ADCY9) Inactivation Protects from Atherosclerosis Only in the Absence of Cholesteryl Ester Transfer Protein (CETP). Circulation. 2018; CIRCULATIONAHA.117.031134

Tardif J-C., Rhainds D., Brodeur M., Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation CLINICAL PERSPECTIVE

« Tardif  J-C., Rheaume E., Lemieux Perreault L-P., et. al. Pharmacogenomic Determinants of the 
Cardiovascular Effects of Dalcetrapib. » Circulation Cardiovascular Genetics. 2015;8:372-382.

« Lindpaintner K., Chasing—and Catching—the Wild Goose, Hypothesis-Free Post-Hoc Stratification Studies as a New Paradigm for Drug Development. » Editorial. Circulation Cardiovascular Genetics. 2015;8:253-255.